Physician profile
Norman Markowitz
NPI 1669425781
$6,319.57
in general payments reported to CMS, 2019-2025
30 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $959 · 2021: $1,387 · 2022: $820 · 2023: $894 · 2024: $738 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,578.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $683.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $581.37 | 2021-2025 | |
| Glaxosmithkline, LLC. | $390.71 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $378.10 | 2019-2025 | |
| Amarin Pharma, INC. | $355.16 | 2019-2021 | |
| Astellas Pharma US INC | $343.05 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $298.42 | 2020-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.70 | 2019-2023 | Ofev |
| Amgen INC. | $257.87 | 2019-2025 | Repatha, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $155.09 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $154.06 | 2020-2023 | |
| Exact Sciences Corporation | $127.27 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $120.84 | 2019 | |
| Allergan, INC. | $119.85 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $68.24 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $59.92 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $56.55 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $55.24 | 2022-2024 | Trintellix |
| Currax Pharmaceuticals LLC | $41.21 | 2020-2021 | |
| Biogen, INC. | $37.36 | 2021 | |
| Sumitomo Pharma America, INC. | $35.05 | 2025 | Gemtesa |
| Abbott Laboratories | $31.52 | 2021-2022 | |
| Alfasigma USA, INC. | $28.51 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.71 | 2025 | Uptravi, Opsumit |
| Radius Health, INC. | $17.56 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.97 | 2021 | |
| Esperion Therapeutics, INC. | $16.37 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.85 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Markowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.